Lurasidone


Atypical antipsychotic with 5-HT7 antagonism

A benzisothiazole atypical antipsychotic with prominent 5-HT7 receptor antagonism contributing to procognitive and antidepressant effects.

Abstract

Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]-cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; CAS 367514-87-2; molecular formula C28H36N4O2S; molecular weight 492.68) is a benzisothiazole atypical antipsychotic developed at Sumitomo Dainippon and approved by the FDA in 2010 under the trade name Latuda. The receptor profile features full D2 antagonism (Ki approximately 1 nM), potent 5-HT2A antagonism (Ki approximately 0.5 nM), 5-HT1A partial agonism (Ki approximately 6.4 nM), and prominent 5-HT7 antagonism (Ki approximately 0.5 nM, the most potent in clinical use). The 5-HT7 antagonism is associated with procognitive effects and improvement in bipolar depression. H1 and muscarinic activity is minimal, producing low sedation and metabolic burden compared to olanzapine and quetiapine; the principal limitation is dose-related akathisia. Plasma half-life is 18 hours; absorption requires food (approximately 350 kcal). Metabolism is via CYP3A4. Approved for schizophrenia (acute and maintenance), bipolar I depression (monotherapy or with lithium/valproate). Used as the reference 5-HT7-prominent antipsychotic.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph